MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Hospital Universitario de Donostia
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (12)
2022
2021
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
2018
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
2016
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89
2015
-
SEOM clinical guidelines in metastatic breast cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 946-955
2013
2012
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5
2010
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814